(Q40415119)

20 September 2017

1 reference

title

Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine (English)

1 reference

20 September 2017

1 reference

1 reference

1

1 reference

20 September 2017

Klinman DM

2

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 October 1995

1 reference

The Journal of Pediatrics

20 September 2017

published in

1 reference

20 September 2017

volume

127

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

518-525

1 reference

Cost-effectiveness of a routine varicella vaccination program for US children

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

The epidemiology of varicella–zoster virus infections: a mathematical model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Live vaccine used to prevent the spread of varicella in children in hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Live attenuated varicella virus vaccine. Efficacy trial in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Lengthy tale of varicella vaccine development finally nears a clinically useful conclusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Molecular epidemiology of live, attenuated varicella virus vaccine in children with leukemia and in normal adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Modification of chicken pox in family contacts by administration of gamma globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Immunisation against chickenpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Current status and prospects of live varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Varicella-zoster virus prevalence in Japan: no significant change in a decade.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Varicella vaccine for healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Vaccines for varicella-zoster virus and cytomegalovirus: recent progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Hell's fire and varicella-vaccine safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

The risk of zoster after varicella vaccination in children with leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Zoster in normal children after varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Childhood vaccination against chickenpox: an analysis of benefits and costs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Routine childhood varicella vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

The epidemiology of varicella–zoster virus infections: the influence of varicella on the prevalence of herpes zoster

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Live Attenuated Varicella Vaccine: Protection in Healthy Adults Compared with Leukemic Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Viral vaccines of the future.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Live attenuated varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Report of Ad Hoc committee on karyological controls of human cell subtrates

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970106-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(95)70106-0

1 reference

20 September 2017

1 reference